Marie Thibault
Stock Analyst at BTIG
(3.25)
# 1,141
Out of 5,182 analysts
129
Total ratings
43.9%
Success rate
3.36%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARAY Accuray | Downgrades: Neutral | n/a | $0.38 | - | 4 | May 7, 2026 | |
| PODD Insulet | Maintains: Buy | $320 → $260 | $154.16 | +68.66% | 8 | May 6, 2026 | |
| EMBC Embecta | Downgrades: Neutral | n/a | $3.64 | - | 5 | May 6, 2026 | |
| HYPR Hyperfine | Initiates: Buy | $2 | $1.69 | +18.34% | 1 | Apr 29, 2026 | |
| ABT Abbott Laboratories | Reiterates: Buy | $131 | $84.32 | +55.36% | 18 | Apr 27, 2026 | |
| EW Edwards Lifesciences | Maintains: Buy | $98 → $100 | $79.96 | +25.06% | 4 | Apr 24, 2026 | |
| BSX Boston Scientific | Maintains: Buy | $90 → $80 | $53.93 | +48.34% | 17 | Apr 22, 2026 | |
| KMTS Kestra Medical Technologies | Reiterates: Buy | $32 | $21.05 | +52.02% | 4 | Apr 7, 2026 | |
| MMED MiniMed Group | Initiates: Buy | $25 | $11.57 | +116.08% | 1 | Mar 31, 2026 | |
| DXCM DexCom | Reiterates: Buy | $85 | $60.61 | +40.24% | 11 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $19 | $11.48 | +65.51% | 5 | Feb 26, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $178.31 | - | 8 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $54 | $26.28 | +105.48% | 8 | Feb 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $15 | $3.70 | +305.95% | 3 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $88 | $55.12 | +59.65% | 5 | Feb 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $20.19 | +48.59% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $215 | $120.66 | +78.19% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.04 | - | 2 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $65 | $71.77 | -9.43% | 8 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.51 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.66 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.03 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $833.08 | -99.28% | 1 | Apr 9, 2020 |
Accuray
May 7, 2026
Downgrades: Neutral
Price Target: n/a
Current: $0.38
Upside: -
Insulet
May 6, 2026
Maintains: Buy
Price Target: $320 → $260
Current: $154.16
Upside: +68.66%
Embecta
May 6, 2026
Downgrades: Neutral
Price Target: n/a
Current: $3.64
Upside: -
Hyperfine
Apr 29, 2026
Initiates: Buy
Price Target: $2
Current: $1.69
Upside: +18.34%
Abbott Laboratories
Apr 27, 2026
Reiterates: Buy
Price Target: $131
Current: $84.32
Upside: +55.36%
Edwards Lifesciences
Apr 24, 2026
Maintains: Buy
Price Target: $98 → $100
Current: $79.96
Upside: +25.06%
Boston Scientific
Apr 22, 2026
Maintains: Buy
Price Target: $90 → $80
Current: $53.93
Upside: +48.34%
Kestra Medical Technologies
Apr 7, 2026
Reiterates: Buy
Price Target: $32
Current: $21.05
Upside: +52.02%
MiniMed Group
Mar 31, 2026
Initiates: Buy
Price Target: $25
Current: $11.57
Upside: +116.08%
DexCom
Mar 9, 2026
Reiterates: Buy
Price Target: $85
Current: $60.61
Upside: +40.24%
Feb 26, 2026
Maintains: Buy
Price Target: $23 → $19
Current: $11.48
Upside: +65.51%
Feb 18, 2026
Downgrades: Neutral
Price Target: n/a
Current: $178.31
Upside: -
Feb 18, 2026
Reiterates: Buy
Price Target: $54
Current: $26.28
Upside: +105.48%
Feb 12, 2026
Maintains: Buy
Price Target: $17 → $15
Current: $3.70
Upside: +305.95%
Feb 6, 2026
Reiterates: Buy
Price Target: $88
Current: $55.12
Upside: +59.65%
Jan 28, 2026
Reiterates: Buy
Price Target: $30
Current: $20.19
Upside: +48.59%
Oct 31, 2025
Maintains: Buy
Price Target: $195 → $215
Current: $120.66
Upside: +78.19%
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.04
Upside: -
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $71.77
Upside: -9.43%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.51
Upside: -
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.66
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $5.03
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $833.08
Upside: -99.28%